Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties, used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure types. It is a Schedule IV controlled substance.
### Primary Indications
* Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
* Other seizure types, though efficacy for conditions other than LGS is less well-established.
### Adult Dosing
* **Lennox-Gastaut Syndrome (LGS):**
* **Initiation:** 5 mg twice daily (BID).
* **Titration:** Increase dose by 5-10 mg every week.
* **Maintenance:** Maximum dose of 20 mg BID.
* **Other Seizure Types:** Dosing is less standardized. Consult specific guidelines or epilepsy specialists.
### Pediatric Dosing
* **Lennox-Gastaut Syndrome (LGS) - 2 years and older:**
* **Initiation:** 5 mg once daily (QD).
* **Titration:** Increase dose by 2.5-5 mg every week.
* **Maintenance:**
* **2 to <10 years or <30 kg:** Maximum dose of 10 mg BID.
* **≥10 years or ≥30 kg:** Maximum dose of 20 mg BID.
* **Note:** For children under 2 years, use is not recommended due to safety concerns. Dosing for other seizure types in pediatrics is not well-established and requires specialist consultation.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Consider a lower starting dose and slower titration. Data is limited.
* **Renal Impairment:** No specific dose adjustment is routinely recommended, but monitor for increased adverse effects.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
### Adverse Effects
* **Common:** Somnolence, lethargy, drooling, constipation, upper respiratory tract infection, fall, vomiting, decreased appetite, ataxia.
* **Serious:** Suicidal behavior and ideation, serious skin reactions (e.g., Stevens-Johnson syndrome), respiratory depression, dependence and withdrawal symptoms, behavioral changes (e.g., aggression, irritability), cognitive impairment.
### Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other sedatives):** Additive CNS depression. Monitor closely for excessive sedation and respiratory depression. Consider dose reduction of one or both agents.
* **CYP2C19 Inhibitors (e.g., fluconazole, omeprazole):** May increase clobazam concentrations. Monitor for increased adverse effects.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam concentrations. Monitor for reduced efficacy.
* **Lacosamide:** Potential for additive PR interval prolongation.
* **Stiripentol:** May increase clobazam concentrations. Dose reduction of clobazam may be necessary.
### Monitoring
* **Seizure frequency and severity:** Assess treatment efficacy.
* **Signs of somnolence and sedation:** Especially during initiation and dose titration.
* **Behavioral changes:** Monitor for suicidal ideation, aggression, and other psychiatric effects.
* **Signs of withdrawal:** If the drug is discontinued, taper slowly.
* **Respiratory status:** Particularly in combination with other respiratory depressants.
* **Skin reactions:** Advise patients to report any rash.
### Clinical Pearls
* Clobazam is often used for refractory epilepsy, particularly LGS.
* Dose-dependent somnolence is a common side effect. Advise patients to avoid activities requiring mental alertness until they know how clobazam affects them.
* Tolerability may decrease over time, necessitating dose adjustments or alternative therapies.
* Abrupt discontinuation can lead to withdrawal symptoms. Taper the dose gradually.
* Due to its active metabolite, N-desmethylclobazam, which has a longer half-life, effects can be prolonged.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.
